MedTrace Logo

Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

NCT07331506 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-01-15

No results posted yet for this study

Summary

Cancer continues to be one of the most significant public health issues worldwide. Thanks to early detection, the mortality rate of certain types of cancer has decreased significantly. However, the lack of accessible, low-cost, non-invasive, non-toxic, and easy-to-implement diagnostic methods results in late diagnoses, leading to 1 in every 6 people dying from cancer today.

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are found both inside cells and in bodily fluids such as blood and urine. Several studies have demonstrated their role in human diseases, especially cancer, where tumors release miRNAs into the bloodstream that can be used as biomarkers for early detection.

The research and development team at Oncoliq SAS identified a panel of miRNAs associated with breast cancer, with a detection performance of 82% sensitivity and 83% specificity, validated in exploratory and preliminary confirmatory studies. These results led to the filing of a patent based on liquid biopsy technology.

The objective of this protocol is to establish a panel of miRNAs for the early detection of breast cancer using samples from breast cancer patients and a cancer-free control group. Validation of the miRNAs will be carried out through RT-qPCR. This stage constitutes the analytical validation of the biomarkers, with the goal of developing an algorithm capable of classifying individuals with and without breast cancer. In future stages, a pilot clinical trial is planned to evaluate test implementation and clinical validation.

Conditions

  • Breast Cancer Detection
  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)
  • Breast Cancer Female
  • Breast Cancer - Ductal Carcinoma in Situ (DCIS)
  • Breast Cancer - Infiltrating Ductal Carcinoma
  • Breast Cancer With Low to Intermediate HER2 Expression
  • Breast Cancer (Early Breast Cancer)
  • Breast Cancer - Female

Interventions

OTHER

Peripheral blood draw

Collection of a blood sample for plasma isolation and miRNA analysis.

Sponsors & Collaborators

  • Oncoliq US Inc

    lead INDUSTRY

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-17
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07331506 on ClinicalTrials.gov